A blood-based liquid biopsy analyzing soluble immune checkpoints and cytokines identifies distinct neuroendocrine tumors
The analysis of soluble immunological factors in blood presents a promising liquid biopsy approach for identifying NENs, delivering critical insights for both prognosis and diagnosis. This study serves as a proof-of-concept for an innovative clinical tool that holds the potential to transform the management of these rare malignancies, providing a non-invasive and effective method for early detection and disease monitoring.
Authors
- Jaime Fernández‐Sarmiento (ORCID: https://orcid.org/0000-0003-2874-2949)
- Marlon Toro
- Nuria Valdés (ORCID: https://orcid.org/0000-0001-5859-257X)
- Vanesa García Moreira
- Eduardo López‐Collazo (ORCID: https://orcid.org/0000-0003-1957-877X)
- Pablo Mata-Martínez (ORCID: https://orcid.org/0009-0005-0929-3908)
- Verónica Terrón‐Arcos
- Carlos del Fresno (ORCID: https://orcid.org/0000-0003-1771-7254)
- Lucía Celada (ORCID: https://orcid.org/0000-0002-3058-7231)
- Francisco J. Cueto (ORCID: https://orcid.org/0000-0002-7457-9583)
- María‐Dolores Chiara (ORCID: https://orcid.org/0000-0002-1112-1583)
- G. Maria
Institutions
- Universidad de Oviedo (ES)
- Universidad Nacional de Educación a Distancia (ES)
- Gobierno del Principado de Asturias (ES)
- Hospital Universitario La Paz (ES)
- Hospital Universitario San Agustín (ES)
- BioCruces Health research Institute (ES)
- Hospital La Paz Institute for Health Research (ES)
- Fundación Hospital de Jove (ES)
- Centre for Biomedical Network Research on Rare Diseases (ES)
- Hospital Universitario Central de Asturias (ES)
- Medical Research Network (US)
- Instituto de Investigación Sanitaria del Principado de Asturias (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1186/s13046-025-03337-3
- Citations
- 4
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 5.42
Funders
- Comunidad de Madrid
- Ministerio de Ciencia, Innovación y Universidades
- Fundación Científica Asociación Española Contra el Cáncer
- Ministerio de Ciencia e Innovación
- Instituto de Salud Carlos III